Documente Academic
Documente Profesional
Documente Cultură
Introduction
Peripartum cardiomyopathy (PPCM) is increasingly rec- symptoms of cardiac congestion, such as abdominal
ognized as an important condition that can complicate discomfort, pleuritic chest pain, and palpitations, can
pregnancy. This disease is associated with a high morbid- also occur. Establishing a diagnosis of PPCM, there-
ity and mortality,14 but its aetiology remains unknown. fore, relies on a high index of suspicion, because early
In 2010, the Working Group on PPCM from the Heart signs and symptoms of heart failure are often not easy
Failure Association of the ESC proposed the following to distinguish from peripartum-associated physiologi-
definition of PPCM: Peripartum cardiomyopathy is an cal discomfort, which can lead to delayed diagnosis.24
idiopathic cardiomyopathy presenting with heart failure In a retrospective review and analysis of 182 patients
secondary to left ventricular systolic dysfunction towards with PPCM, diagnosis was delayed by >1week in 48%
the end of pregnancy or in the months following deliv- of patients who later experienced a major adverse event
ery, where no other cause of heart failure is found. It is (death, heart transplantation, or defibrillator implanta-
a diagnosis of exclusion. The left ventricle may not be tion).8 A thorough medical history of the exact onset of
dilated but the ejection fraction is nearly always reduced symptoms in relation to pregnancy, and subsequent diag-
below 45%.4 PPCM phenotypically resembles the cardiac nostic confirmation of left ventricular systolic dysfunc-
characteristics of dilated cardiomyopathy (DCM), but the tion by echocardiography, MRI, or both, are important.
condition is considered an independent disease, distinct Furthermore, a thorough evaluation is necessary to elimi-
Department of from other cardiomyopathies.1 nate other potential cardiac and noncardiac explanations
Cardiology and Physicians are often faced with the difficulty of dis- for a patients clinical presentation.
Angiology, Medical
School Hannover, Carl tinguishing between peripartum discomfort in healthy Various underlying mechanisms have been proposed,
Neuberg Strasse1, women (such as fatigue, mild shortness of breath, or including a low selenium level, viral infections, stress-
30625 Hannover,
Germany (D.H.K.).
mild oedema), and the pathological symptoms of PPCM. activated cytokines, inflammation and autoimmune
Hatter Institute Importantly, PPCM can present either very dramati- reactions, and a pathological response to haemodynamic
forCardiovascular cally, with acute heart failure necessitating admission to stress.3,9 Data now suggest a common pathway on which
Research in Africa,
Department of intensive care, or subtly over several weeks. Generally, various aetiologies that induce PPCM might converge.
Medicine & IIDMM, however, PPCM manifests in the final weeks of preg- This pathway includes unbalanced oxidative stress and a
Faculty of Health
Sciences, University
nancy or within the first months after delivery in previ- high level of the nursing hormone prolactin, which leads
ofCape Town, ously healthy women (Figure1), mainly through typical to the production of an angiostatic and proapoptotic
CapeTown 7935, symptoms of heart failure, such as dyspnoea, exercise 16kDa fragment of prolactin that seems to initiate and
South Africa (K.S.).
intolerance, cough, and orthopnoea. 37 Nonspecific propagate the disease.10,11 The 16kDa form of prolactin
Correspondence to: mainly affects the endothelium and might, together with
D.H.K.
hilfiker.denise@ Competing interests additional antiangiogenic factors such as soluble fms-
mh-hannover.de The authors declare no competing interests. like tyrosine kinase1 (sFLT1; also known as vascular
17%
24%
43% 43%
57%
40% 73%
Antepartum
13 Months postpartum
36 Months postpartum
Figure 1 | Time of onset of symptoms of peripartum cardiomyopathy according to country. a | South Africa.9 b | Germany.7
c | USA.6
Bromocriptine Placenta
sFLT-1
CCL2 Akt ROS
NF-B
Recruitment of SOD2
inflammatory cells
CCL2 rVEGF
STAT3 PGC-1
Recruitment of
VEGF inflammatory cells VEGF
Figure 2 | Pathophysiological mechanisms in PPCM. Prolactin is released from the pituitary gland and, under conditions
ofoxidative stress in the myocardium, is proteolytically cleaved to a 16kDa fragment by proteases, such as cathepsinD
ormatrix metalloproteinases. InPPCM, this process is induced by increased oxidative stress owing to downregulation of
the transcription factors STAT3 and PGC1 and their targets (such as SOD2), or by increased Akt activation, which also
suppresses cardiac SOD2 expression. The 16kDa prolactin leads to increased microRNA146a expression in endothelial
cells, which exerts angiostatic effects and impairs the metabolic activity of cardiomyocytes. The 16kDa prolactin also
enhances CCL2 expression in endothelial cells via NFB signalling. Additionally, increased levels of IFN and full-length
prolactin promote the upregulation of CCL2 in cardiomyocytes, generating local inflammation in theheart, which is
associated with a particularly poor prognosis. STAT3 and PGC1 are also needed to protect the cardiac vasculature
fromadditional antiangiogenic factors present in the peripartum phase, such as sFLT1. Both transcription factors
increasethe cardiac expression of VEGF, which neutralizes the adverse effects of sFLT1. Blocking prolactin, neutralizing
microRNA146a, or treating with a VEGF agonist might, therefore, be therapeutic options for PPCM. Abbreviations: Akt,
RAC serine/threonine-protein kinase (also known as protein kinaseB); CCL2, CC motif chemokine2; NFB, nuclear
factorNFB; PGC1, peroxisome proliferator-activated receptor coactivator1; PPCM, peripartum cardiomyopathy; ROS,
reactive oxygen species; rVEGF, recombinant vascular endothelial growth factor; sFLT1, soluble fmslike tyrosine kinase1
(also known as vascular endothelial growth factor receptor1); SOD2, mitochondrial superoxide dismutase[Mn]; STAT3,
signal transducer and activator of transcription3; VEGF, vascular endothelial growth factor.
partial rescue from PPCM, whereas blocking prolac- on cardiomyocytes, the molecule induces the release of
tin with bromocriptine completely prevented the onset miR146a-loaded exosomes from endothelial cells, which
ofPPCM.11 enter cardiomyocytes. Exosomal-derived miR146a
The 16kDa form of prolactin inhibits angiogenesis downregulates receptor tyrosine-protein kinaseerbB4
atvarious levels by inducing endothelial cell cycle arrest at in cardiomyocytes and, as a consequence, decreases the
the G0G1 and G2M stages,48 in parallel with inhibition metabolic activity of the cells and impairs endothelial-
of mitogen-activated protein kinase activation induced by to-cardiomyocyte communication via the neuregulin1
basic fibroblast growth factor and VEGF.49 Additionally, erbB signalling system.10 The biological mechanisms
16kDa prolactin induces endothelial-cell apoptosis by by which 16kDa prolactin affects cardiac cells are
activating caspase3 and nuclear factor (NF)B,50 inhib- summarized in Figure2.
its endothelial-cell migration by downregulating the Evidence suggests that the angiostatic and proapoptotic
RasTiam1Rac1Pak1 signalling pathway,51 and attenu- 16kDa prolactin might have a causal role in the initiation
ates the activation of endothelial nitric oxide synthase, and progression of PPCM. Suppression of prolactin release
which blocks vasodilatation.52,53 Finally, 16kDa prolac- using the D2dopamine-receptor agonist bromocriptine
tin enhances endothelial inflammation by promoting prevented the onset of disease in several animal models
leukocyte adhesion to endothelial cells.54 The biological of PPCM (Stat3/, cardiomyocyte-specific Ppargc1a/,
effects of 16kDa prolactin have been extensively reviewed and cardiomyocyte-specific overexpression of Akt1).11,12
previously.42 The 16kDa prolactin is known not to signal This notion is supported by initial clinical data from case
via the prolactin receptors, but a receptor of its own has reports and small studies, which show that the addition
not been identified. However, 16kDa prolactin activates of bromocriptine to standard therapy for heart failure
NFB signalling in endothelial cells and thereby upregu- is associated with improvement in both left ventricular
lates microRNA146a (miR146a), which mediates most function and a composite clinical outcome (remaining in
of the adverse effects of 16kDa prolactin in endothelial NYHA functional classIIIIV, failure to improve ejection
cells.10 Although 16kDa prolactin has little direct effect fraction by >10absolute units, and death) in women with
acute severe PPCM.11,34,5557 However, the combination by high levels of circulating pregnancy hormones, such
of bromocriptine and standard therapy for heart failure as oestrogens.11,65,66 Given that PI3KAkt signalling is
must be tested in large, multicentre, randomized, con- known to promote physiological hypertrophy and cardio
trolled trials. We are currently performing such a trial in protection, this pathway might, at least partly, be responsi-
Germany, where we aim to randomly allocate 60patients ble for the adaptation and protection of the maternal heart
with PPCM to standard therapy for heart failure with or during pregnancy. After delivery, mechanical stress and
without the addition ofbromocriptine.58 oestrogen levels rapidly decrease, and PI3KAkt signal-
ling is no longer activated.11 We tested the hypothesis that
VEGF signalling and pre-eclampsia activating cardiac Akt signalling in the peripartum phase
Another antiangiogenic factor that is released in high might protect mice predisposed to develop PPCM (the
quantities from the placenta during mid-to-late gestation Stat3/ model of PPCM crossed with a cardiomyocyte-
is sFLT1. A markedly elevated serum level of sFLT1 has restricted, constitutively-active Akt1 transgene [Stat3/;
been associated with pre-eclampsia, a common maternal CAkt1tg]).14 Surprisingly, both CAkt1tg and Stat3/;CAkt1tg
complication of mid-to-late gestation that affects 35% mice developed PPCM with systolic dysfunction.14 Both
of pregnancies worldwide.5961 Clinically, pre-eclampsia genotypes displayed cardiac hypertrophy and reduced
causes cardiac dysfunction independently of blood pres- capillary density associated with decreased expression
sure.59,62 Some reports indicate that pre-eclampsia fre- of SOD2, enhanced oxidative stress, and an increased
quently occurs in patients who subsequently develop level of miR146a, which indicates increased production
PPCM,7,12,15 and a potential connection between the two of the antiangiogenic 16kDa prolactin.14 Additionally,
diseases has been established. Ppargc1a/ mice develop cardiac inflammation and fibrosis were accelerated in
PPCM that is associated with an increased level of sFlt1 Stat3/;CAkt1tg mice compared with Stat3/ mice, which
and insufficient upregulation of cardiac expression of was associated with increased postpartum mortality.14 The
Vegf, a potent proangiogenic factor that is antagonized prolactin blocker bromocriptine prevented heart failure
by sFlt1.12 As mentioned above, this model of PPCM also and the decrease in capillary density in the CAkt1tg and
shows compromised protection from oxidative stress and Stat3/;CAkt1tg mice, which indicates that prolactin has a
enhanced cleavage of prolactin. PPCM was ameliorated by central role in these two novel models of PPCM.
the addition of recombinant VEGF (rVEGF) or bromo Subsequent analyses showed that even full-length
criptine, but full rescue from PPCM was obtained only prolactin might contribute to the pathology of PPCM,
with the combination of rVEGF and bromocriptine. This because it upregulates the proinflammatory CC motif
result suggests that PPCM might be a two-hit phenom chemokine2 (CCL2).14 We have previously observed in
enon. Firstly, systemic antiangiogenic signals occur a cohort of African women with PPCM that increased
during late pregnancy (as are present in pre-eclampsia). levels of prolactin and IFN correlated with both a sus-
Secondly, antiangiogenic factors are further upregulated tained inflammatory state and poor prognosis.13 In addi-
during the peripartum phase, together with host suscep- tion to prolactin, IFN also induced CCL2 expression in
tibility in the form of insufficient local proangiogenic cardiomyocytes, which was mediated via activation of Akt
defences in the heart.12 signalling.14 These data suggest that the combination of
This model supports the idea that PPCM might start as prolactin and a high level of IFN might be detrimental
a disease of the endothelium, leading to loss or damage in patients with PPCM. Akt activation might be protec-
of the vasculature. As a consequence, functional insuf- tive for the maternal heart during pregnancy, but needs
ficiency of the heart owing to impaired blood flow is to be downregulated in the peripartum phase. Agents
likely. This process might be initiated during pregnan- that increase Akt activation in the peripartum phase are,
cies complicated by pre-eclampsia, in which sFLT1 is therefore, not likely to be appropriate therapies for heart
markedly upregulated, and predispose these patients failure in PPCM.
to PPCM. Therefore, therapies that target several anti
angiogenic factors in PPCM might be successful. The Biomarkers
latest data from a German registry 7 show that the overall A diagnosis of PPCM should be considered whenever
rate of both partial and full recovery of patients treated a woman presents with symptoms of systolic heart
with bromocriptine (96%) is higher than that in other failure during the peripartum period. Biomarkers such
studies, although the rate of full recovery is similar to that as an elevated level of Nterminal pro-brain natriuretic
in previous studies (summarized previously 63). peptide (NTproBNP) are indicative of heart failure in
peripartum women.7 Likewise, an inability to downregu-
Inflammation late serum IFN might predict an adverse outcome in
Patients who survive PPCM often tolerate subsequent patients with PPCM.13 However, both NTproBNP and
pregnancies fairly well, particularly if cardiac function IFN are fairly nonspecific markers for heart failure.
has fully recovered.4,64 However cardiac dysfunction fre- Unlike patients with most other forms of cardiomyo
quently re-emerges in the peripartum and postpartum pathy, those with PPCM have a high likelihood of recov-
phases.4,64 Therefore, the state of pregnancy might be ery with adequate therapy. Therefore, risk stratification
protective even for damaged hearts. On the molecular and management of patients are important to rule out
level, PI3KAkt signalling is highly activated during other aetiologies of heart failure, such as underlying
pregnancy, partly by increased mechanical stress, but also DCM or genetic cardiomyopathy.
A direct downstream effector of 16kDa prolac- heart merge in a common pathway, in which increased
tin, miR146a, has emerged as a promising potential oxidative stress and subsequent generation of 16kDa pro-
diagnostic marker to distinguish between PPCM and lactin impairs the cardiac vasculature and metabolism,
other cardiomyopathies.7,10 The observation that miR- finally culminating in systolic heart failure and PPCM
146a is released in specific microparticles (endothelial (Figure2). The 16kDa prolactin pathophysiology seems
exos omes) from endothelial cells exposed to 16kDa to be common to patients with PPCM of various aetio
prolactin is consistent with the discovery that micro- logies and from different geographical regions. More
particle profiles differ substantially between patients over, initial evidence suggests that 16kDa prolactin and
with PPCM and those with DCM.67 Nevertheless, addi- its downstream mediators are specific to patients with
tional biomarkers are needed to distinguish between PPCM, which might allow their use as biomarkers for
PPCM and other types of heart failure, to optimize the diagnostic and prognostic purposes in women with peri-
diagnosis, management, and risk stratification of these partum heart failure. Experimental and clinical evidence
young patients. supports the benefit of bromocriptine in treating women
with PPCM, although further data are required from
Conclusions large-scale clinical trials. Activators of Akt signalling
Increased awareness of PPCM has benefitted patients seem to be detrimental in PPCM, whereas VEGF agonists
with this condition. As clinical data sets are collected and and neutralization of miR146a might be novel therapies
analysed, insight into the pathophysiology of the disease for this condition.
will be improved, providing important information for
the diagnosis and management of these patients. A large, Review criteria
international registry of patients with PPCM has been
A search of the PubMed database was performed using
initiated by the ESC via the EURObservational Research the following terms: peripartum cardiomyopathy,
Programme.31 Data from 1,000 patients with PPCM, preeclampsia, heart failure, prolactin, and
collected via this programme, will help to improve preeclampsia and heart failure around pregnancy.
our understanding of the aetiology, e pidemiology, and Theliterature cited in this Review derives mainly from
optimal treatment of this condition. the years 2000 to 2014. We selected only full-text, peer-
Experimentally, dysregulation of multiple factors, reviewed articles published in English. We searched the
reference lists of selected papers for further leads.
including STAT3, PGC1, and Akt,11,12,14 in the peripartum
1. Pearson, G.D. etal. Peripartum cardiomyopathy: 11. Hilfiker-Kleiner, D. etal. A cathepsinD-cleaved 21. Desai, D., Moodley, J. & Naidoo, D. Peripartum
National Heart, Lung, and Blood Institute and 16kDa form of prolactin mediates postpartum cardiomyopathy: experiences at King EdwardVIII
Office of Rare Diseases (National Institutes of cardiomyopathy. Cell 128, 589600 (2007). Hospital, Durban, South Africa and a review of
Health) workshop recommendations and review. 12. Patten, I.S. etal. Cardiac angiogenic imbalance the literature. Trop. Doct. 25, 118123 (1995).
JAMA 283, 11831188 (2000). leads to peripartum cardiomyopathy. Nature 22. Chapa, J.B. etal. Prognostic value of
2. Selle, T., Renger, I., Labidi, S., Bultmann, I. 485, 333338 (2012). echocardiography in peripartum cardiomyopathy.
&Hilfiker-Kleiner, D. Reviewing peripartum 13. Forster, O. etal. Reversal of IFN, oxLDL and Obstet. Gynecol. 105, 13031308 (2005).
cardiomyopathy: current state of knowledge. prolactin serum levels correlate with clinical 23. Gentry, M.B. etal. African-American women
Future Cardiol. 5, 175189 (2009). improvement in patients with peripartum havea higher risk for developing peripartum
3. Sliwa, K., Fett, J. & Elkayam, U. Peripartum cardiomyopathy. Eur. J. Heart Fail. 10, 861868 cardiomyopathy. J. Am. Coll. Cardiol. 55, 654659
cardiomyopathy. Lancet 368, 687693 (2006). (2008). (2010).
4. Sliwa, K. etal. Current state of knowledge on 14. Ricke-Hoch, M. etal. Opposing roles of Akt 24. Modi, K.A., Illum, S., Jariatul, K., Caldito, G. &
aetiology, diagnosis, management, and therapy andSTAT3 in protection of the maternal heart Reddy, P.C. Poor outcome of indigent patients with
of peripartum cardiomyopathy: a position from peripartum stress. Cardiovasc. Res. 101, peripartum cardiomyopathy in the United States.
statement from the Heart Failure Association 587596 (2014). Am. J. Obstet. Gynecol. 201, 171.e1e5 (2009).
ofthe European Society of Cardiology Working 15. Kamiya, C.A. etal. Different characteristics of 25. Goland, S., Modi, K., Hatamizadeh, P.
Group on Peripartum Cardiomyopathy. Eur. Heart J. peripartum cardiomyopathy between patients & Elkayam,U. Differences in clinical profile
12, 767778 (2010). complicated with and without hypertensive ofAfricanAmerican women with peripartum
5. Demakis, J.G. & Rahimtoola, S.H. Peripartum disorders: results from the Japanese Nationwide cardiopmyopathy in the United States. J. Card.
cardiomyopathy. Circulation 44, 964968 (1971). survey of peripartum cardiomyopathy. Circ. J. 75, Fail. 19, 214218 (2013).
6. Elkayam, U. etal. Pregnancy-associated 19751981 (2011). 26. Blauwet, L.A. etal. Predictors of outcome in
cardiomyopathy: clinical characteristics and a 16. Brar, S.S. etal. Incidence, mortality, and racial 176South African patients with peripartum
comparison between early and late presentation. differences in peripartum cardiomyopathy. Am. J. cardiomyopathy. Heart 99, 308313 (2013).
Circulation 111, 20502055 (2005). Cardiol. 100, 302304 (2007). 27. Mielniczuk, L.M. etal. Frequency of peripartum
7. Haghikia, A. etal. Phenotyping and outcome on 17. Fett, J.D. Peripartum cardiomyopathy: insights cardiomyopathy. Am. J. Cardiol. 97, 17651768
contemporary management in a German cohort from Haiti regarding a disease of unknown (2006).
of patients with peripartum cardiomyopathy. etiology. Minn. Med. 85, 4648 (2002). 28. European Society of Cardiology. PeriPartum
Basic Res. Cardiol. 108, 366 (2013). 18. Fett, J.D., Christie, L.G., Carraway, R.D. CardioMyopathy (PPCM) Registry [online],
8. Goland, S. etal. Clinical profile and predictors &Murphy, J.G. Five-year prospective study of http://www.escardio.org/guidelines-surveys/
ofcomplications in peripartum cardiomyopathy. theincidence and prognosis of peripartum eorp/surveys/ppcm/Pages/peripartum-
J. Card. Fail. 15, 645650 (2009). cardiomyopathy at a single institution. Mayo Clin. cardiomyopathy.aspx (2014).
9. Sliwa, K. etal. Peripartum cardiomyopathy: Proc. 80, 16021606 (2005). 29. Elkayam, U. Clinical characteristics of
inflammatory markers as predictors of outcome 19. Kuklina, E.V. & Callaghan, W.M. Cardiomyopathy peripartum cardiomyopathy in the United
in 100 prospectively studied patients. Eur. Heart J. and other myocardial disorders among States:diagnosis, prognosis, and management.
27, 441446 (2006). hospitalizations for pregnancy in the United States: J. Am. Coll. Cardiol. 58, 659670 (2011).
10. Halkein, J. etal. MicroRNA146a is a therapeutic 20042006. Obstet. Gynecol. 115, 93100 (2010). 30. Safirstein, J.G. etal. Predictors of left
target and biomarker for peripartum 20. Fett, J.D. etal. Unrecognized peripartum ventricularrecovery in a cohort of peripartum
cardiomyopathy. J. Clin. Invest. 123, 21432154 cardiomyopathy in Haitian women. Int. J. Gynaecol. cardiomyopathy patients recruited via the
(2013). Obstet. 90, 161166 (2005). internet. Int. J. Cardiol. 154, 2731 (2012).
31. Sliwa, K. etal. EURObservational Research conditions. J. Cell Sci. 117, 51555164 57. Sliwa, K. etal. Evaluation of bromocriptine
Programme: a worldwide registry on peripartum (2004). inthetreatment of acute severe peripartum
cardiomyopathy (PPCM) in conjunction with the 45. Ferrara, N., Clapp, C. & Weiner, R. The 16K cardiomyopathy: a proof-of-concept pilot study.
Heart Failure Association of the European fragment of prolactin specifically inhibits basal Circulation 121, 14651473 (2010).
Society of Cardiology Working Group on PPCM. or fibroblast growth factor stimulated growth of 58. US National Library of Medicine. ClinicalTrials.gov
Eur. J. Heart Fail. http://dx.doi.org/10.1002/ capillary endothelial cells. Endocrinology 129, [online], http://clinicaltrials.gov/ct2/show/
ejhf.68. 896900 (1991). NCT00998556 (2012).
32. Pearl, W. Familial occurrence of peripartum 46. Piwnica, D. etal. CathepsinD processes 59. Bello, N., Rendon, I.S. & Arany, Z. The relationship
cardiomyopathy. Am. Heart J. 129, 421422 humanprolactin into multiple 16K-like between pre-eclampsia and peripartum
(1995). Nterminal fragments: study of their cardiomyopathy: a systematic review and meta-
33. Pierce, J.A., Price, B.O. & Joyce, J.W. antiangiogenic properties and physiological analysis. J. Am. Coll. Cardiol. 62, 17151723
Familialoccurrence of postpartal heart failure. relevance. Mol.Endocrinol. 18, 25222542 (2013).
Arch.Intern. Med. 111, 651655 (1963). (2004). 60. Rana, S. etal. Angiogenic factors and the risk
34. Meyer, G.P. etal. Bromocriptine treatment 47. Macotela, Y. etal. Matrix metalloproteases ofadverse outcomes in women with suspected
associated with recovery from peripartum fromchondrocytes generate an antiangiogenic preeclampsia. Circulation 125, 911919 (2012).
cardiomyopathy in siblings: two case reports. 16kDa prolactin. J. Cell Sci. 119, 17901800 61. Shahul, S. etal. Subclinical left ventricular
J.Med. Case Reports 4, 80 (2010). (2006). dysfunction in preeclamptic women with
35. Fett, J.D., Sundstrom, B.J., Etta King, M. 48. Tabruyn, S.P., Nguyen, N.Q., Cornet, A.M., preserved left ventricular ejection fraction:
&Ansari, A.A. Motherdaughter peripartum Martial, J.A. & Struman, I. The antiangiogenic a 2D speckle-tracking imaging study.
cardiomyopathy. Int. J. Cardiol. 86, 331332 factor, 16kDa human prolactin, induces Circ.Cardiovasc. Imaging 5, 734739 (2012).
(2002). endothelial cell cycle arrest by acting at both the 62. Powe, C.E., Levine, R.J. & Karumanchi, S.A.
36. van Spaendonck-Zwarts, K. etal. Peripartum G0G1 and the G2M phases. Mol. Endocrinol. Preeclampsia, a disease of the maternal
cardiomyopathy as part of familial dilated 19, 19321942 (2005). endothelium: the role of antiangiogenic factors
cardiomyopathy. Circulation 121, 21692175 49. DAngelo, G. etal. 16K human prolactin inhibits and implications for later cardiovascular
(2010). vascular endothelial growth factor-induced disease. Circulation 123, 28562869 (2011).
37. Morales, A. etal. Rare variant mutations activation of Ras in capillary endothelial cells. 63. Fett, J.D. Earlier detection can help avoid
inpregnancy-associated or peripartum Mol. Endocrinol. 13, 692704 (1999). manyserious complications of peripartum
cardiomyopathy. Circulation 121, 21762182 50. Tabruyn, S.P. etal. The antiangiogenic factor cardiomyopathy. Future Cardiol. 9, 809816
(2010). 16K human prolactin induces caspase- (2013).
38. van Spaendonck-Zwarts, K.Y. etal. Titin gene dependent apoptosis by a mechanism that 64. Elkayam, U. etal. Maternal and fetal outcomes
mutations are common in families with both requires activation of nuclear factorB. of subsequent pregnancies in women with
peripartum cardiomyopathy and dilated Mol.Endocrinol. 17, 18151823 (2003). peripartum cardiomyopathy. N. Engl. J. Med. 344,
cardiomyopathy. Eur. Heart J. http://dx.doi.org/ 51. Lee, S.H., Kunz, J., Lin, S.H. & Yu-Lee, L.Y. 15671571 (2001).
10.1093/eurheartj/ehu050. 16kDa prolactin inhibits endothelial cell migration 65. Chung, E., Yeung, F. & Leinwand, L.A. Akt and
39. Bahl, A., Swamy, A., Sharma, Y. & Kumar, N. by down-regulating the RasTiam1Rac1Pak1 MAPK signaling mediate pregnancy-induced
Isolated noncompaction of left ventricle signaling pathway. Cancer Res. 67, 1104511053 cardiac adaptation. J. Appl. Physiol. (1985) 112,
presenting as peripartum cardiomyopathy. Int. J. (2007). 15641575 (2012).
Cardiol. 109, 422423 (2006). 52. Gonzalez, C. etal. 16K-prolactin inhibits 66. Eghbali, M. etal. Molecular and functional
40. Lea, B., Bailey, A.L., Wiisanen, M.E., Attili, A. & activation of endothelial nitric oxide synthase, signature of heart hypertrophy during pregnancy.
Rajagopalan, N. Left ventricular noncompaction intracellular calcium mobilization, and Circ. Res. 96, 12081216 (2005).
presenting as peripartum cardiomyopathy. Int. J. endothelium-dependent vasorelaxation. 67. Walenta, K. etal. Circulating microparticles
Cardiol. 154, e65e66 (2012). Endocrinology 145, 57145722 (2004). asindicators of peripartum cardiomyopathy.
41. Rehfeldt, K.H., Pulido, J.N., Mauermann, W.J. 53. Gonzalez, C. etal. Elevated vasoinhibins may Eur.Heart J. 33, 14691479 (2012).
&Click, R.L. Left ventricular hypertrabeculation/ contribute to endothelial cell dysfunction and
noncompaction in a patient with peripartum low birth weight in preeclampsia. Lab. Invest. Acknowledgements
cardiomyopathy. Int. J. Cardiol. 139, e18e20 87,10091017 (2007). We thank Sylvia Dennis (Hatter Institute for
(2010). 54. Nguyen, N.Q. etal. Inhibition of tumor growth Cardiovascular Research in Africa, University of Cape
42. Hilfiker-Kleiner, D., Struman, I., Hoch, M., and metastasis establishment by adenovirus- Town, South Africa) for proofreading the manuscript.
Podewski, E. & Sliwa, K. 16kDa prolactin and mediated gene transfer delivery of the The authors are supported by the Deutsche Forschungs
bromocriptine in postpartum cardiomyopathy. antiangiogenic factor 16K hPRL. Mol. Ther. 15, Gesellschaft (DFG), the Bundesministeriums
Curr. Heart Fail. Rep. 9, 174182 (2012). 20942100 (2007). frBildung und Forschung (BMBF), the National
43. Toescu, V., Nuttall, S.L., Martin, U., Kendall, M.J. 55. Habedank, D. etal. Recovery from peripartum ResearchFoundation South Africa, and the
& Dunne, F. Oxidative stress and normal cardiomyopathy after treatment with MedicalResearch Foundation SouthAfrica.
pregnancy. Clin. Endocrinol. (Oxf.) 57, 609613 bromocriptine. Eur. J. Heart Fail. 10, 11491151
(2002). (2008). Author contributions
44. Lkhider, M., Castino, R., Bouguyon, E., Isidoro, C. 56. Hilfiker-Kleiner, D. etal. Recovery from Both authors researched data for the article,
& Ollivier-Bousquet, M. CathepsinD released by postpartum cardiomyopathy in 2 patients by contributed substantially to discussion of its content,
lactating rat mammary epithelial cells is involved blocking prolactin release with bromocriptine. wrote the manuscript, and reviewed and edited it
in prolactin cleavage under physiological J.Am. Coll. Cardiol. 50, 23542355 (2007). before submission.